Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

OBJECTIVE: Crizotinib can target against mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK), which has been considered as a multi-targeted tyrosine kinase inhibitor (TKI). The objective of this study was to explore the efficacy of crizotinib in advanced non-small-cell lung...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:BMC Cancer
Main Authors: Chen, Rui-Lian, Zhao, Jun, Zhang, Xu-Chao, Lou, Na-Na, Chen, Hua-Jun, Yang, Xue, Su, Jian, Xie, Zhi, Zhou, Qing, Tu, Hai-Yan, Zhong, Wen-Zhao, Yan, Hong-Hong, Guo, Wei-Bang, Wu, Yi-Long, Yang, Jin-Ji
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2018
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6258481/
https://ncbi.nlm.nih.gov/pubmed/30477470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-5078-y
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים